Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Greenrise Global Brands Inc. operates in the specialty and generic drug manufacturing sector, focusing on developing and marketing cannabis-based pharmaceuticals. The company's competitive position is bolstered by its proprietary formulations and established distribution networks in Canada and select international markets.
Greenrise generates revenue primarily through the sale of cannabis-based pharmaceuticals, leveraging its proprietary formulations that offer unique therapeutic benefits. The company has established a strong distribution network, particularly in Canada, which allows for competitive pricing and market penetration.
Regulatory changes impacting cannabis legalization in key markets
Advancements in proprietary drug formulations
Partnerships with healthcare providers for distribution
Market acceptance of cannabis-based treatments
Ongoing regulatory changes in cannabis legislation could impact market access and product approval timelines.
Technological disruption in drug formulation and delivery methods may outpace current capabilities.
Emergence of new entrants in the cannabis pharmaceutical space could dilute market share.
Established pharmaceutical companies entering the cannabis market may leverage their distribution networks.
Negative operating cash flow raises concerns about liquidity and operational sustainability.
High reliance on R&D funding could strain financial resources if revenue does not materialize.
moderate - While healthcare spending is generally resilient, demand for specialty drugs can be sensitive to economic downturns affecting consumer spending.
Higher interest rates could increase financing costs for R&D and operational expansion, negatively impacting profitability and valuation multiples.
minimal - The company has a negative debt/equity ratio, indicating a lack of reliance on external financing.
growth - Investors looking for exposure to the expanding cannabis pharmaceutical market.
high - The stock has demonstrated significant volatility, with a 3-month return of -66.7%.